From the Journals

Which migraine medications are most effective?


 

For relief of acute migraine, triptans, ergots, and antiemetics are two to five times more effective than ibuprofen, and acetaminophen is the least effective medication, new results from large, real-world analysis of self-reported patient data show.

METHODOLOGY:

  • Researchers analyzed nearly 11 million migraine attack records extracted from Migraine Buddy, an e-diary smartphone app, over a 6-year period.
  • They evaluated self-reported treatment effectiveness for 25 acute migraine medications among seven classes: acetaminophen, NSAIDs, triptans, combination analgesics, ergots, antiemetics, and opioids.
  • A two-level nested multivariate logistic regression model adjusted for within-subject dependency and for concomitant medications taken within each analyzed migraine attack.
  • The final analysis included nearly 5 million medication-outcome pairs from 3.1 million migraine attacks in 278,000 medication users.

TAKEAWAY:

  • Using ibuprofen as the reference, triptans, ergots, and antiemetics were the top three medication classes with the highest effectiveness (mean odds ratios [OR] 4.80, 3.02, and 2.67, respectively).
  • The next most effective medication classes were opioids (OR, 2.49), NSAIDs other than ibuprofen (OR, 1.94), combination analgesics acetaminophen/acetylsalicylic acid/caffeine (OR, 1.69), and others (OR, 1.49).
  • Acetaminophen (OR, 0.83) was considered to be the least effective.
  • The most effective individual medications were eletriptan (Relpax) (OR, 6.1); zolmitriptan (Zomig) (OR, 5.7); and sumatriptan (Imitrex) (OR, 5.2).

IN PRACTICE:

“Our findings that triptans, ergots, and antiemetics are the most effective classes of medications align with the guideline recommendations and offer generalizable insights to complement clinical practice,” the authors wrote.

Woman with headache laflor/gettyimages

SOURCE:

The study, with first author Chia-Chun Chiang, MD, Department of Neurology, Mayo Clinic, Rochester, Minnesota, was published online November 29 in Neurology.

LIMITATIONS:

The findings are based on subjective user-reported ratings of effectiveness and information on side effects, dosages, and formulations were not available. The newer migraine medication classes, gepants and ditans, were not included due to the relatively lower number of treated attacks. The regression model did not include age, gender, pain intensity, and other migraine-associated symptoms, which could potentially affect treatment effectiveness.

DISCLOSURES:

Funding for the study was provided by the Kanagawa University of Human Service research fund. A full list of author disclosures can be found with the original article.

A version of this article first appeared on Medscape.com.

Recommended Reading

A large proportion of migraine patients are not offered preventive treatment
Clinician Reviews
Pandemic survey: Forty-six percent of pediatric headache patients got worse
Clinician Reviews
Headache is a common post–COVID-19 complaint
Clinician Reviews
Is mindfulness key to helping physicians with mental health?
Clinician Reviews
About 19% of COVID-19 headaches become chronic
Clinician Reviews
Autoimmune disorder drugs top list of meds linked to headache
Clinician Reviews
Promising new tool for better migraine management in primary care
Clinician Reviews
Headache for inpatients with COVID-19 may predict better survival
Clinician Reviews
Recommending exercise for migraine: Just do it
Clinician Reviews
Atogepant prevents episodic migraine in some difficult-to-treat cases
Clinician Reviews